Abstract
Maintenance treatment with rituximab is at this date approved for relapsed follicular lymphoma (FL) patients, when at least partial remission after induction chemotherapy has been achieved. Results of studies in first line treatment of FL are promising, final results of PRIMA study are highly expected.
The role of maintenance treatment with rituximab in aggressive lymphoma are controversial, it´s role is not well defined.